-
公开(公告)号：US20050197370A1
公开(公告)日：2005-09-08
申请号：US11073227
申请日：2005-03-04
IPC分类号： C07D413/10 , C07D413/12 , A61K31/422 , C07D413/02
CPC分类号： C07D413/12 , C07D413/10
摘要： The present invention provides the compounds of formula I-A their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
摘要翻译： 本发明提供式IA化合物其药学上可接受的盐或酯，对映异构体形式，非对映异构体和外消旋体，上述化合物的制备，含有它们的药物组合物及其制备方法以及使用上述 控制或预防疾病如癌症的化合物。
-
公开(公告)号：US08703130B2
公开(公告)日：2014-04-22
申请号：US13570333
申请日：2012-08-09
申请人： Monika Baehner , Ulrich Brinkmann , Guy Georges , Remko Albert Griep , Sabine Imhof-Jung , Anita Kavlie , Hubert Kettenberger , Christian Klein , Joerg Thomas Regula , Wolfgang Schaefer , Juergen Michael Schanzer , Werner Scheuer , Stefan Seeber , Markus Thomas
发明人： Monika Baehner , Ulrich Brinkmann , Guy Georges , Remko Albert Griep , Sabine Imhof-Jung , Anita Kavlie , Hubert Kettenberger , Christian Klein , Joerg Thomas Regula , Wolfgang Schaefer , Juergen Michael Schanzer , Werner Scheuer , Stefan Seeber , Markus Thomas
IPC分类号： A61K39/395
CPC分类号： C07K16/22 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/30
摘要： The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译： 本发明涉及针对人VEGF和针对人ANG-2的双特异性抗体，其制备方法，含有所述抗体的药物组合物及其用途。
-
公开(公告)号：US20130078251A1
公开(公告)日：2013-03-28
申请号：US13590904
申请日：2012-08-21
申请人： Olivier Freytag , Guy Georges , Ekkehard Moessner , Olaf Mundigl , Gérald Tuffin , Pablo Umana
发明人： Olivier Freytag , Guy Georges , Ekkehard Moessner , Olaf Mundigl , Gérald Tuffin , Pablo Umana
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/3053 , C07K2317/24 , C07K2317/33 , C07K2317/41 , C07K2317/732 , C07K2317/92
摘要： The invention provides anti-MCSP antibodies and methods of using the same.
摘要翻译： 本发明提供抗MCSP抗体及其使用方法。
-
公开(公告)号：US20120213774A1
公开(公告)日：2012-08-23
申请号：US13402399
申请日：2012-02-22
申请人： Georg Fertig , Jens Fischer , Guy Georges , Klaus Kaluza , Valeria Lifke , Joerg Moelleken , Sonja Offner , Achal Pashine , Stefan Seeber
发明人： Georg Fertig , Jens Fischer , Guy Georges , Klaus Kaluza , Valeria Lifke , Joerg Moelleken , Sonja Offner , Achal Pashine , Stefan Seeber
IPC分类号： A61K39/395 , C12N15/13 , C12N15/63 , C12N5/10 , A61P11/06 , C12N1/21 , C12P21/00 , A61P19/02 , A61P1/04 , C07K16/24 , C12N1/19
CPC分类号： C07K16/2866 , A61K39/395 , A61K39/39558 , A61K2039/505 , C07K2317/24 , C07K2317/30 , C07K2317/76 , C07K2317/92
摘要： An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
摘要翻译： 结合IL33R的抗体，其特征在于重链可变结构域包含SEQ ID NO：1的CDR3区，SEQ ID NO：2的CDR2区和SEQ ID NO：3的CDR1区，并且其中轻链可变区 结构域包含SEQ ID NO：4的CDR3区，SEQ ID NO：5的CDR2区和SEQ ID NO：6的CDR1区或嵌合，人源化或T细胞表位缺失的抗体变体具有治疗的有利性质 的炎性疾病。
-
公开(公告)号：US08003099B2
公开(公告)日：2011-08-23
申请号：US12586893
申请日：2009-09-29
申请人： Johannes Auer , Nikolaos Dimoudis , Guy Georges , Petra Hanke , Hendrik Knoetgen , Ekkehard Moessner , Claire Louise Langrish
发明人： Johannes Auer , Nikolaos Dimoudis , Guy Georges , Petra Hanke , Hendrik Knoetgen , Ekkehard Moessner , Claire Louise Langrish
IPC分类号： A61K39/00 , A61K39/395
CPC分类号： C07K16/244 , C07K2317/76 , Y10S530/809
摘要： An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.
摘要翻译： 结合IL-17的抗体，其特征在于与单克隆抗体3C1结合的相同的IL-17表位结合，并且在铰链区在氨基酸位置216-240，优选在氨基酸位置220-修饰的人IgG1同种型， 240，CH1和CH2之间和/或在CH2和CH3之间的氨基酸位置327-331的第二区域间区域具有治疗炎性疾病的有利性质。
-
公开(公告)号：US20070179151A1
公开(公告)日：2007-08-02
申请号：US11637733
申请日：2006-12-12
申请人： Li Chen , Guy Georges , Alfred Mertens , Xihan Wu
发明人： Li Chen , Guy Georges , Alfred Mertens , Xihan Wu
IPC分类号： A61K31/496 , A61K31/5377 , A61K31/4709 , C07D403/14 , C07D409/14 , C07D403/02
CPC分类号： C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14
摘要： The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
摘要翻译： 本发明涉及式I化合物：其药学上可接受的盐或酯，对映体形式，非对映异构体和外消旋体，这些化合物的制备，含有它们的药物组合物及其制备，以及这些化合物在对照中的用途 或预防癌症等疾病。
-
17.发明授权Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent 有权缀合于治疗或诊断剂的双特异性抗体和地高辛的复合物公开(公告)号：US08907069B2
公开(公告)日：2014-12-09
申请号：US13382502
申请日：2010-07-05
申请人： Ulrich Brinkmann , Rebecca Croasdale , Wilma Dormeyer , Guy Georges , Alexander Haas , Eike Hoffmann , Silke Metz , Olaf Mundigl , Werner Scheuer , Jan Olaf Stracke
发明人： Ulrich Brinkmann , Rebecca Croasdale , Wilma Dormeyer , Guy Georges , Alexander Haas , Eike Hoffmann , Silke Metz , Olaf Mundigl , Werner Scheuer , Jan Olaf Stracke
IPC分类号： C07K16/46 , A61K51/10 , A61K49/00 , A61K47/48 , C07K16/28 , B82Y5/00 , C12N15/113 , A61K39/395 , C07K16/16 , C07K16/44 , C07K16/32 , C12N15/11 , A61K31/704 , A61K39/00
CPC分类号： C07K16/44 , A61K31/704 , A61K39/39533 , A61K47/6879 , A61K47/6897 , A61K49/0045 , A61K49/0058 , A61K2039/505 , B82Y5/00 , C07K16/16 , C07K16/2803 , C07K16/2863 , C07K16/2896 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/77 , C07K2317/92 , C07K2319/30 , C12N15/111 , C12N15/1138 , C12N2310/14 , C12N2310/3513 , C12N2320/32 , A61K2300/00
摘要： The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译： 本发明涉及a）针对靶蛋白的双特异性抗体和抗体片段的复合物，和b）与治疗或诊断试剂缀合的地高辛，其生产方法，它们作为治疗或诊断试剂的递送平台的用途， 含有所述抗体的药物组合物及其用途。
-
公开(公告)号：US08859737B2
公开(公告)日：2014-10-14
申请号：US12971300
申请日：2010-12-17
申请人： Birgit Bossenmaier , Nikolaos Dimoudis , Thomas Friess , Guy Georges , Irene Kolm , Hans-Willi Krell , Valeria Lifke , Ekkehard Moessner
发明人： Birgit Bossenmaier , Nikolaos Dimoudis , Thomas Friess , Guy Georges , Irene Kolm , Hans-Willi Krell , Valeria Lifke , Ekkehard Moessner
CPC分类号： C07K16/32 , A61K2039/505 , C07K16/40 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译： 本发明涉及与人HER3（抗HER3抗体）结合的抗体，其制备方法，含有所述抗体的药物组合物及其用途。
-
公开(公告)号：US08785153B2
公开(公告)日：2014-07-22
申请号：US13402399
申请日：2012-02-22
申请人： Georg Fertig , Jens Fischer , Guy Georges , Klaus Kaluza , Valeria Lifke , Joerg Moelleken , Sonja Offner , Achal Pashine , Stefan Seeber
发明人： Georg Fertig , Jens Fischer , Guy Georges , Klaus Kaluza , Valeria Lifke , Joerg Moelleken , Sonja Offner , Achal Pashine , Stefan Seeber
IPC分类号： C12P21/08
CPC分类号： C07K16/2866 , A61K39/395 , A61K39/39558 , A61K2039/505 , C07K2317/24 , C07K2317/30 , C07K2317/76 , C07K2317/92
摘要： An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
摘要翻译： 结合IL33R的抗体，其特征在于重链可变结构域包含SEQ ID NO：1的CDR3区，SEQ ID NO：2的CDR2区和SEQ ID NO：3的CDR1区，并且其中轻链可变区 结构域包含SEQ ID NO：4的CDR3区，SEQ ID NO：5的CDR2区和SEQ ID NO：6的CDR1区或嵌合，人源化或T细胞表位缺失的抗体变体具有治疗的有利性质 的炎性疾病。
-
公开(公告)号：US20120282280A1
公开(公告)日：2012-11-08
申请号：US13382505
申请日：2010-06-30
申请人： Birgit Bramlage , Ulrich Brinkmann , Rebecca Croasdale , Simone Dill , Wilma Dormeyer , Guy Georges , Michael Grote , Alexander Haas , Eike Hoffman , Ludger Markus Ickenstein , Kerstin Jahn-Hofman , Matthias John , Silke Metz , Olaf Mundigl , Werner Scheuer , Jan Olaf Stracke
发明人： Birgit Bramlage , Ulrich Brinkmann , Rebecca Croasdale , Simone Dill , Wilma Dormeyer , Guy Georges , Michael Grote , Alexander Haas , Eike Hoffman , Ludger Markus Ickenstein , Kerstin Jahn-Hofman , Matthias John , Silke Metz , Olaf Mundigl , Werner Scheuer , Jan Olaf Stracke
CPC分类号： C07K16/44 , A61K31/704 , A61K39/39533 , A61K47/6879 , A61K47/6897 , A61K49/0045 , A61K49/0058 , A61K2039/505 , B82Y5/00 , C07K16/16 , C07K16/2803 , C07K16/2863 , C07K16/2896 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/77 , C07K2317/92 , C07K2319/30 , C12N15/111 , C12N15/1138 , C12N2310/14 , C12N2310/3513 , C12N2320/32 , A61K2300/00
摘要： This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical 5 compositions containing said antibodies, and uses thereof.
摘要翻译： 本发明涉及针对靶蛋白和半抗原的双特异性抗体和抗体片段，其中半抗原是PEG或生物素，最优选地高辛，其制备方法，它们作为治疗或诊断剂的递送平台的用途，含有 所述抗体及其用途。
-
-
-
-
-
-
-
-
-
搜索结果
42 条记录 (耗时 0.044 秒)
